Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01210079 · ClinicalTrials.gov registry record · Phase 2
Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?
A Phase 2 study of Opioid-Induced Hyperalgesia, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT01210079 is a Phase 2 study of Opioid-Induced Hyperalgesia that has completed, run by University of California, Los Angeles. The registered enrollment target is 26 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01210079, a Phase 2 study of Opioid-Induced Hyperalgesia, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
Utilizing a double-blind, placebo-controlled design, the proposed work will evaluate the ability of an adjuvant anticonvulsant analgesic to diminish or reverse the opioid-induced hyperalgesia complicating the pain states suffered by Methadone-Maintained (MM) patients. Specifically, in a sample of MM patients, gabapentin, which has proven efficacy in treating neuropathic pain will be evaluated for its ability to ameliorate or diminish the opioid-induced hyperalgesia in these patients as reflected by changes on pain threshold and tolerance to both cold-pressor and electrical pain, at peak and through methadone blood levels. The results of this work will not only provide pharmacologic insight into the mechanisms underlying poor pain tolerance in this at-risk population, but also direction for the medical management of pain complicated by opioid-induced hyperalgesia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Gabapentin;
Study Locations (1)
California
- UCLA School of Nursing - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2002-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01210079
The ClinicalTrials.gov registry entry for NCT01210079 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid-Induced Hyperalgesia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01210079 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01210079 about?
NCT01210079 is a clinical study titled "Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?". Utilizing a double-blind, placebo-controlled design, the proposed work will evaluate the ability of an adjuvant anticonvulsant analgesic to diminish or reverse the opioid-induced hyperalgesia complicating the pain states suffered by Methadone-Maintained (MM) patients. Specifically, in a sample of MM...
What is the current status of trial NCT01210079?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2002-09. Estimated completion is 2010-05.
What conditions does trial NCT01210079 study?
This clinical trial studies the following conditions: Opioid-Induced Hyperalgesia.
What interventions are being tested in trial NCT01210079?
The interventions under investigation include: Placebo (DRUG), Gabapentin; (DRUG).
Who is sponsoring clinical trial NCT01210079?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01210079 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.